Presence of donor specific HLA class 2 antibodies (DSA class 2) is associated with development of graft fibrosis more than 10 years after liver transplantation–a retrospective single center study

Here the impact of donor specific human leukocyte antigen (HLA) class 2 antibodies (DSA cl 2) on long term outcome after liver transplantation (LT) was investigated. Altogether 156 (44 pediatric and 112 adult) LT recipients were included in study. Graft fibrosis assessed by elastography biopsy. DSA determined Luminex technology. 46% positive for a median follow-up 15 years. In multivariate analysis significantly associated with immunosuppressive monotherapy (OR 5.42; 95% CI: 1.02–28.90; p = .048). Compared to negative patients, had more graft based stiffness (mean 9.4 ± 9.0 kPa vs. 6.5 6.3 kPa; < .002) stages (p .016) performed biopsies .002). Also, higher incidence chronic rejections (11% 2%; .045) losses (6% 0%; .043) found. regression 4.57; CI 1.59–13.10; .005). So, these data suggest that development occurs often may ultimately result rejection fibrosis.